hepatocellular-carcinoma

Documents about hepatocellular-carcinoma

• Dual-ligand-modified cantharidin nanoparticles for the treatment of hepatocellular carcinoma via the inhibition of Ephb4#261766Figshare
• Combination Therapy with HSP90 Inhibitors and NanoPulse Stimulation Synergistically Impedes Hepatocellular Carcinoma and Breast Cancer Growth in Mice#289048ODU Digital Commons
• Table 3_Uncovering cellular perturbations and key mediator communications in liver cancer using single-cell RNA sequencing.xlsx#325703Figshare
• Table 2_Uncovering cellular perturbations and key mediator communications in liver cancer using single-cell RNA sequencing.xlsx#325704Figshare
• Table 4_Uncovering cellular perturbations and key mediator communications in liver cancer using single-cell RNA sequencing.xlsx#325705Figshare
• Computation of contrast-enhanced perfusion using only two CT scan phases: a proof-of-concept study on abdominal organs#354261IRIS
• A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)#363604ClinicalTrials.gov
• A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer#834037ClinicalTrials.gov
• AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer#893332ClinicalTrials.gov
• Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery#909797ClinicalTrials.gov
• DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors#854313ClinicalTrials.gov
• Data Sheet 1_Uncovering cellular perturbations and key mediator communications in liver cancer using single-cell RNA sequencing.pdf#325702Figshare
• Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma#393550Scholar Commons
• Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization#838478ClinicalTrials.gov
• Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation#867957ClinicalTrials.gov
• Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC#884583ClinicalTrials.gov
• Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer#900423ClinicalTrials.gov
• A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies#830569ClinicalTrials.gov
• Integrative Profiling of Metabolic CYP Expression, DNA Mutation Rates, and Immune Cell Infiltration for Survival Prognosis in Hepatocellular Carcinoma / Mona Dawood, Axel Guthart, Ednah Ooko, Ralf Weiskirchen, Thomas Efferth, Joelle C. Boulos#628969Deutsche Nationalbibliothek
• Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery#837346ClinicalTrials.gov
• Score System for Prediction Risk and Early Diagnosis of HCC in HIV/HCV Patients#849067ClinicalTrials.gov
• A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients#872283ClinicalTrials.gov
• Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patients#202504HAL (France)
• Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors#332761ClinicalTrials.gov
• Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery#846208ClinicalTrials.gov
• Hepatocyte-specific Versus Extracellular Contrast Agents for Liver MRI: Prospective, Intra-individual Comparison of Diagnostic Performance for Hepatocellular Carcinoma#855555ClinicalTrials.gov
• Title of Manuscript: Development and Internal-external Validation of a Comprehensive Model for Predicting Risk of Post-RFA Recurrence in HCC Patients#866465ClinicalTrials.gov
• Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI#889150ClinicalTrials.gov
• A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.#807674ClinicalTrials.gov
• MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)#844803ClinicalTrials.gov
• A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.#882756ClinicalTrials.gov
• Additional file 2 of Elucidating the beneficial effects of gut microbiota-derived metabolites in treating hepatocellular carcinoma: an integrated network pharmacology, molecular docking, and single-cell sequencing analysis#780719Figshare
• Additional file 1 of Elucidating the beneficial effects of gut microbiota-derived metabolites in treating hepatocellular carcinoma: an integrated network pharmacology, molecular docking, and single-cell sequencing analysis#780720Figshare
• Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors#860039ClinicalTrials.gov
• Neoplastic risk in hyperplastic esophagogastric junction lesions: Comprehensive multicenter study#176782HAL (France)
• Hepatic arterial infusion or intravenous infusion of adebrelimab, combined with bevacizumab and HAIC of the FOLFOX regimen for advanced unresectable hepatocellular carcinoma (HAIBrave-001 trial): a study protocol of a prospective, double-arm, phase II trial.#666100NCBI PubMed Central
• Vaccine Therapy in Treating Patients With Liver Cancer#882780ClinicalTrials.gov
• National Registry and Blood Bank of Patients With Liver Cancer#903087ClinicalTrials.gov
• Supplemental Material for: Effectiveness and safety of atezolizumab plus bevacizumab combined with transarterial chemoembolization as conversion therapy for initially unresectable hepatocellular carcinoma in real-world clinical practice in China (TALENTRUE): a multicenter, retrospective, observational cohort study#451863Figshare
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors#804465ClinicalTrials.gov
• Combined Fluorocholine Positron Emission Tomography and Magnetic Resonance Imaging (FCH-PET/MRI) in Curative Treatment of a Hepatocellular Carcinoma#811317ClinicalTrials.gov
• Mild Hypothermia and Acute Kidney Injury in Liver Transplantation#825517ClinicalTrials.gov
• Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant#831692ClinicalTrials.gov
• Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver#896326ClinicalTrials.gov
• Bevacizumab plus iparomlimab/tuvonralimab with hepatic artery infusion chemotherapy followed by stereotactic body radiotherapy in patients with BCLC stage C hepatocellular carcinoma with thrombus and/or extrahepatic oligometastases (BITS-TO-HCC): study protocol of a prospective, single-center, single-arm, phase II study.#404508NCBI PubMed Central
• A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation#849201ClinicalTrials.gov
• HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial#812376ClinicalTrials.gov
• Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls#634702eScholarship
• An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.#861942ClinicalTrials.gov
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)#162475ClinicalTrials.gov